Kristie L. Kahl

At the 37th Annual Miami Breast Cancer Conference, Dr. Kevin S. Hughes discussed genetic testing and what health care providers should be doing to identify more individuals at risk for cancer.

Xentuzumab in combination with Verzenio, with or without endocrine therapy, may be safe and effective in treating patients with solid tumors and advanced breast cancer.

Premenopausal women with HR-positive, HER2-negative advanced breast cancer experienced improved survival and quality of life with the addition of Kisqali to Zoladex and endocrine therapy to their treatment regimen.

Women who had contralateral prophylactic mastectomy reported similar breast satisfaction and quality of life, cancer-related distress and anxiety and depression scores, compared with those who did not undergo the procedure.

In this episode of the “CURE Talks Cancer” podcast, we spoke with the co-chair of the MMRF’s Laugh for Life event, as well as this year’s “Spirit of Hope” award recipient.

Here is a list of the recent trial initiations that occurred within the cancer space in February.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Andrew Ciupek, from the Go2 Foundation for Lung Cancer, on the importance of biomarker testing and targeted therapy options for patients with non-small cell lung cancer.

MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.

The Food and Drug Administration granted a priority review to the new drug application for lurbinectedin to treat patients with small cell lung cancer.

After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.

The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Bishoy Tadros, who went on to break barriers after he was diagnosed with acute lymphoblastic leukemia at the age of 3 and immigrated to the United States from Egypt to receive treatment.

The Food and Drug Administration granted a priority review to KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Study findings showed that eradicating Helicobacter pylori infection reduced the risk of developing gastric cancer by 73% in those with a first-degree relative with the disease, compared with individuals in whom infection was persistent.

In this episode of the “CURE Talks Cancer” podcast, we spoke with a survivor on two very rare types of cancer, called pheochromocytoma and paraganglioma, and why more research behind these two diseases can help put together the pieces of the cancer puzzle.

Older survivors face increased symptom burden, which in turn affects their well-being, highlighting the need for cancer-related symptom surveillance and intervention.

The refinement of surgical treatment of cancer was named the American Society of Clinical Oncology’s advance of the year, according to its Annual Report on Progress Against Cancer.

A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.

Patients with head and neck paragangliomas, a rare neuroendocrine tumor type, may be safely and effectively treated with proton therapy.

Ahead of Rare Disease Day, here is what you need to know about pheochromocytoma and paraganglioma, two rare types of tumors.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Zsofia Stadler, on behalf of the Colon Cancer Foundation, about the rising incidence of early-age onset colorectal cancer.

Here is a list of the recent trial initiations that occurred within the cancer space in January.

A microsimulation model found that evolving approaches are associated with improved life expectancy among childhood cancer survivors – particularly for those who received chemotherapy alone.

In a first-of-its-kind analysis, researchers found that high body mass index may be associated with improved survival in Tecentriq-treated patients with advanced non–small cell lung cancer.

A study of the Veterans Affairs health system found that, despite trends suggesting otherwise, African American men with prostate cancer had similar survival outcomes, compared with non-Hispanic White men.

Survival among patients with myelofibrosis who discontinued treatment with Jakafi appeared to have poorer survival, which was most prominent in those who stopped during the blast phase of treatment.

In this week’s episode, a pair who is forever connected by their genetic risk for cancer talked about the revelations that came from a study they participated in that changed both of their lives.

Patients with high-risk stage 3 melanoma who experienced an immune-related side effect after treatment with adjuvant Keytruda had reduced risk for disease recurrence, compared with those on the placebo arm.

The Food and Drug Administration granted a priority review to belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma.